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CARDIOVASCULAR AND RENAL MECHANISMS 
























Adapted from Dzau, V. AM Heart J. 1991; 121 : 1244-1263 and Nelson R.G., NEJM 1996; 28 : 1636-1642.
5Risque d’événement CV fatal à 10 ans
SCORE belge
Risque à 10 ans de MCV 
fatales dans des 
populations à risque 
moyen de maladies 
cardiovasculaires
15 % et plus
10 % – 14 %
5 % - 9 %




Adapté d’après De Backer 
















Olijhoek J. et al. 
Eur Heart J, 2004.
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Diagnostic Criteria for Metabolic 
Syndrome (NCEP ATP III)
Diagnosis is made when 3 or more 
of these risk criteria are met
JAMA 2001, 285, 2486 & Circulation 2004, 109, 433.



































































BP-lowering trials in 













2. That tighter BP
control is better
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MYOCARDIAL INFARCTION
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MICROVASCULAR DISEASE
Relation PA et complications
ACCORD BP Study: 
Primary and Secondary Outcomes
• Patients with T2D (GFR N, no µAlb) and hypertension (N = 
4733)
• Random assignment
– Intensive therapy: target SBP < 120 mm Hg
– Standard therapy: target SBP < 140 mm Hg
• 1°outcome: nonfatal MI, nonfatal stroke, death fro m CV 
causes
• Mean follow-up = 4.7 yOutcome Intensive Standard HR P-value
SBP after 1 year (mmHg) 119.3 133.5 NR NR
1° outcome (annual rate) 1.87 2.09 0.88 .20
Death from any cause (annual rate) 1.28 1.19 1.07 .55
Stroke (annual rate) 0.32 0.53 0.59 .01
AEs (rate) 3.3 1.3 NR <.001
The ACCORD Study Group. N Engl J Med. 
2010 March 14. [Epub ahead of print].
ACCORD: Significant Differences in 
AEs and Laboratory Measures
Outcome Intensive Standard P-value
Event due to BP medications (%)a 3.3 1.27 < .001
Hypotension (%) 0.7 0.04 < .001
Hyperkalemia (%) 0.4 0.04 .01
eGFR < 30 mL/min/1.73m2 (%) 4.2 2.2 < .001
eGFR (mL/min/1.73m2) 74.8 80.6 < .001
Urinary albumin: Cr (mg/g) 12.6 14.9 < .001
Macroalbuminuria (%) 6.6 8.7 .009
The ACCORD Study Group. N Engl J Med. 
2010 March 14. [Epub ahead of print].
a Lower BP in intensive group associated with greater 
exposure to drugs from every class.

DeHoff-Cooper R et.al. JAMA 2010;304:61-68.





















SBP > 140 mmHg
SBP 130–140 mmHg
SBP < 130 mmHg
OUTCOMES: (MI, stroke, all-cause mortality)
Patient Characteristic No Diabetes All Diabetes High Risk Diabetes**
Number of Patients 4559 6946 2842
Male 3,009 (66%)* 3,954 (57%) 1,830 (64%)*
Female 1,550 (34%)* 2,992 (43%) 1,012 (36%)*
Age 69.8 (7.0)* 67.5 (6.6) 66.9 (7.2)*
Age > 65 yrs 3,344 (73)* 4,296 (62) 1,668 (59)*
Caucasian 4,075 (89%)* 5,537 (80%) 2,277 (80%)
Black 374 (8%)* 1042 (15%) 429 (15%)
ACCOMPLISH Study
Baseline Patient Characteristics
* Significant differences from “All Diabetes” cohort
** Patients with diabetes and history of cardiac events, stroke, or renal disease
Values are absolute numbers (%) or mean (SD)
Adapted from: Weber MA, et al. J Am Coll Cardiol. 2010;56:77-85.
Bakris G et.al. in preparation.


















Not controlled (n = 972)
Usual control (n = 4724)
Tight control (n = 1,250)
SBP > 140 mmHg
SBP 130–140 mmHg
SBP < 130 mmHg
OUTCOMES: (MI, stroke, revascularization, all-cause mortality)

25
Valeurs cibles de la PAS
chez les patients diabétiques
Lignes directrices ESC/ESH 2007
< 140/90 mmHg pour tous les patients hypertendus
< 130/80 mmHg pour les patients diabétiques et ceux avec 
risque CV élévé à très élevé
Lignes directrices ESH 2009
< 140/90 mm Hg pour tous les patients hypertendus
ESC ESH Guidelines for the management of arterial hypertension, Journal of Hypertension 2007, 25:1105–1187
ESH Updated guidelines, J Hypertension 2009
2000 : Apport majeur des IEC sur le plan 
CV et rénal en prévention secondaire 







































d’origine CV IM AVC
Néphropathie
Macroprotéinurique
Etude Micro- HOPE (n = 3577 diabétiques)

ONTARGET Non-Inferiority Comparison
0.6 0.7 0.8 0.9 1.0 1.1 1.2 1.3 1.4
RR (95% CI)
Note that the outcomes are presented as point estimates with confidence intervals. The solid line






Telmisartan better Ramipril better
Occurrence of Microalbuminuria during the 48-Month Follow-up 
Period in the Two Study Groups. ROADMAP
Haller H et al. N Engl J Med 2011;364:907-917.
Secondary Efficacy End Points during the Double-Blind Treatment Period. 
ROADMAP
Haller H et al. N Engl J Med 2011;364:907-917.
Adler et al (UKPDS Group). Kidney Int 2003, 63, 225-32.
NATURAL HISTORY OF DIABETIC NEPHROPATHY  IN TYPE 2 DIABETES
2 goals :  Prevent 1) End-stage renal disease   2) Death (cardiovascular)
Schrier RW et al. (2007) Appropriate blood pressure control in hypertensive and normotensive type 2 
diabetes mellitus: a summary of the ABCD trial Nat Clin Pract Nephrol 3: 428–438
Progressive increases in urinary albumin excretion rate are associated with 
decreased survival in patients with type 2 diabetes
Progression of diabetic nephropathy 
in IRMA 2 study of hypertensive patients with 
type 2 diabetes and microproteinuria
Mitch, W. E. N Engl J Med 2004;351:1934-1936
ACE Inhibition versus Angiotensin-Receptor Blockade in Nephropathy 
Associated with Type 2 Diabetes
ARAII
Diabète type 2, néphropathie, 
utilisation des ARA






Suppression du système rénine avec les ARAPlacebo




1 Weber & Giles. 2006



















Mean change from baseline in mean sitting BP at Week 12 (mmHg)
*p≤0.001 vs Irbesartan











Proportion of patients achieving BP control (%)












HCTZ 25 mg alone
BP control defined as BP <140/90 mmHg
* p<0.05, ** p<0.01 vs aliskiren/HCTZ
Class 1/2 obesity: BMI of 30–39.9 kg/m2; class 3 obesity: BMI ≥40 kg/m2
Prescott MF, et al. 2007
More Obese Patients Achieve BP Control with 




Aliskiren penetrates adipose 
& skeletal muscle tissue
 Activation of the RAAS in adipose tissue and skeletal muscles of obese patients 
may be a contributory factor in the development of hypertension and metabolic 
abnormalities
Aliskiren penetrates adipose 
& skeletal muscle tissue
 Interstital fluid, tissue biopsy and blood samples were taken for drug and RAS biomarker 
assessment on the last day of the placebo run-in period and of the aliskiren and amlodipine 
treatments periods (days 42 and 98 respectively)
 Mean and median [ aliskiren] in the interstitial fluid of sleletal muscle and adipose tissue were 
above the in vitro IC50 for renin (0.33ng/ml) and of similar order of magnitude to plasma aliskiren 
concentrations.  Aliskiren remained detectable 8 weeks after the last dose
12-14 semaines









Etude ouverte Double aveugle
+
Titration forcée à la semaine 12; toutes les doses ont été administrées une fois par jour
0
Semaine
Parving et al. N Engl J Med 2008
Étude randomisée en double aveugle avec contrôle par placebo chez des 
patients hypertendus atteints de diabète de type 2 et de néphropathie
Aliskiren in the eValuation of 
prOteinuria In Diabetes (AVOID)
Dual blockade of the renin-angiotensin system :
In Diabetic nephropathy
AVOID Study : mean GFR 67 ml/min , Losartan +Aliskiren vs 
+Placebo
• Hypertensive patients with diabetes type II &  nephropathy 
(n=599)
• Follow-up : 6 months
• Primary outcome :reduction in the urinary albumin/creatinine 
ratio
 combination of aliskiren with losartan provides an additional reduction 
in UACR of 20% compared with losartan alone.
N Eng J Med 2008; 358: 2433-2446
CONCLUSION :
Objectifs pour le SM et/ou le DT2
• Arrêt du tabac
• Exercice physique quotidien
• Réduction du NaCl alimentaire
• BMI <25 Kg/m²
• HbA1c <6,5%
• PA < 140/90 mmHg (plus bas si pas coronarien): IEC en 
premier choix, mais association souvent nécessaire
(débat AC vs D).
• Place de l’aliskiren (Rasilez°) à définir, mais pers pectives 
encourageantes)
• LDL-chol <1g/l (même plus bas stt DT à haut risque CV)
• MA <30 mg/24h
• Aspirine faible dose 
